1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Documento de consenso de enfermería en asma 2020 Translated title: Asthma 2020 Nursing Consensus Document

      other

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          El asma es una enfermedad respiratoria de carácter crónico que presenta un riesgo de exacerbaciones. Un buen manejo y seguimiento continuo de los pacientes es fundamental para un control adecuado de la enfermedad, la cual requiere tanto medidas farmacológicas como no farmacológicas para su tratamiento. El personal de enfermería especializada en asma puede contribuir al correcto manejo de los pacientes asmáticos. Este tiene un papel fundamental en las pruebas diagnósticas, en la administración de medicamentos, en el seguimiento de los casos y en su educación. Este consenso nació de la necesidad de abordar un aspecto del manejo de la enfermedad que no cuenta con recomendaciones específicas en las guías actuales. Este documento destaca y actualiza el papel del personal de enfermería especializada en el cuidado y manejo de las personas con asma, para ofrecer una serie de conclusiones y recomendaciones prácticas con el objetivo de mejorar su implicación en el abordaje de esta patología. Las recomendaciones que se proponen son el resultado de un consenso de tipo nominal desarrollado a lo largo del año 2019 y fueron validadas a comienzos del año 2020.

          Translated abstract

          Asthma is a chronic respiratory disease which presents with a risk of exacerbations. Good patient management and continuous monitoring are crucial for good disease control, and pharmacological and non-pharmacological interventions are essential for proper treatment. Nurses specialised in asthma can contribute to the correct management of asthmatic patients. They play a key role in diagnostic tests, administration of medication, and patient follow-up and education. This consensus arose from the need to address an aspect of asthma management that does not appear in the specific recommendations of current guidelines. This document highlights and updates the role of specialized nurses in the care and management of asthma patients, offering conclusions and practical recommendations with the aim of improving their contribution to the treatment of this disease. Proposed recommendations appear as the result of a nominal consensus which was developed during 2019, and validated at the beginning of 2020.

          Related collections

          Most cited references130

          • Record: found
          • Abstract: not found
          • Article: not found

          Standardisation of spirometry.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

            Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophilic inflammation. They were randomly assigned (in a 1:1:1:1 ratio) to receive one of three doses of intravenous mepolizumab (75 mg, 250 mg, or 750 mg) or matched placebo (100 mL 0·9% NaCl) with a central telephone-based system and computer-generated randomly permuted block schedule stratified by whether treatment with oral corticosteroids was required. Patients received 13 infusions at 4-week intervals. The primary outcome was the rate of clinically significant asthma exacerbations, which were defined as validated episodes of acute asthma requiring treatment with oral corticosteroids, admission, or a visit to an emergency department. Patients, clinicians, and data analysts were masked to treatment assignment. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01000506. 621 patients were randomised: 159 were assigned to placebo, 154 to 75 mg mepolizumab, 152 to 250 mg mepolizumab, and 156 to 750 mg mepolizumab. 776 exacerbations were deemed to be clinically significant. The rate of clinically significant exacerbations was 2·40 per patient per year in the placebo group, 1·24 in the 75 mg mepolizumab group (48% reduction, 95% CI 31-61%; p<0·0001), 1·46 in the 250 mg mepolizumab group (39% reduction, 19-54%; p=0·0005), and 1·15 in the 750 mg mepolizumab group (52% reduction, 36-64%; p<0·0001). Three patients died during the study, but the deaths were not deemed to be related to treatment. Mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma. GlaxoSmithKline. Copyright © 2012 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

              Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts.
                Bookmark

                Author and article information

                Contributors
                Journal
                Open Respir Arch
                Open Respir Arch
                Open Respiratory Archives
                Elsevier
                2659-6636
                08 January 2021
                Jan-Mar 2021
                08 January 2021
                : 3
                : 1
                : 100079
                Affiliations
                [a ]Servicio de Neumología, CEP Hermanos Sangro, Hospital General Universitario Gregorio Marañón, Madrid, España
                [b ]Servicio de Neumología, Hospital General Universitario de Alicante, Alicante, España
                [c ]Servicio de Neumología y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, España
                [d ]Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, España
                [e ]Servicio de Neumología, Hospital Universitario de Vic, Barcelona, España
                [f ]Servicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, España
                [g ]Unidad de Asma, Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Sevilla, España
                [h ]Servicio de Neumología, Hospital Universitario A Coruña, A Coruña, España
                [i ]Servicio de Neumología y Cirugía Torácica, Hospital Universitario Nuestra Señora de Candelaria, Sta. Cruz de Tenerife, España
                Author notes
                [* ]Autor para correspondencia. davdiaper82@ 123456gmail.com
                Article
                S2659-6636(20)30091-6 100079
                10.1016/j.opresp.2020.100079
                10369614
                20678b28-3946-4400-9921-1595c5b1a3ed
                © 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Neumología y Cirugía Torácica (SEPAR).

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 5 October 2020
                : 30 November 2020
                Categories
                Documento De Consenso

                asma,enfermería,recomendaciones de consenso,asthma,nursing,consensus recommendations

                Comments

                Comment on this article